SITAZIT DM ER 10/1000 MG 10S

About

SITAZIT DM ER 10/1000 MG 10S is an extended-release oral medication combining Dapagliflozin and Metformin, indicated for the management of type 2 diabetes mellitus in adults. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and a reduction in blood glucose levels, independent of insulin. Metformin, a biguanide, works by decreasing glucose production in the liver, reducing glucose absorption from the gut, and improving the body's sensitivity to insulin. The extended-release formulation of Metformin allows for once-daily dosing, improving patient adherence. This combination provides comprehensive glycemic control, helps with weight management, and offers cardiovascular and renal benefits, making it a valuable option for many patients with type 2 diabetes.

Uses

• Treatment of type 2 diabetes mellitus
• Improvement of glycemic control
• Adjunct to diet and exercise
• For patients inadequately controlled on monotherapy

Directions For Use

Take one tablet orally once daily with the evening meal, or as directed by your healthcare provider. Swallow whole; do not crush or chew.

Benefits

• Lowers blood glucose effectively
• Promotes weight loss
• Offers cardiovascular benefits
• Provides renal protective effects
• Once-daily dosing for convenience
• Reduces hepatic glucose production

Side Effects

• Genital yeast infections
• Urinary tract infections
• Increased urination
• Nausea and diarrhea
• Hypoglycemia (especially with other agents)
• Dizziness
• Back pain
• Flu-like symptoms
• Ketoacidosis (rare)
• Lactic acidosis (rare, with Metformin)
• Dehydration
• Vitamin B12 deficiency (long-term Metformin)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of lactic acidosis with Metformin and ketoacidosis with Dapagliflozin.
• Pregnancy - Not recommended during the second and third trimesters. Consult a doctor for alternative management.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk. Consult a doctor.
• Liver - Use with caution in mild to moderate liver impairment. Contraindicated in severe liver disease due to Metformin.
• Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m²). Dose adjustment needed for moderate impairment.
• Lung - No direct impact on lung conditions. However, severe respiratory failure can increase lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.